Navigation Links
FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree
Date:3/22/2011

SILVER SPRING, Md., March 22, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that Terumo Cardiovascular Systems Corporation (TCVS) of Ann Arbor, Mich., and two of its officers, Mark A. Sutter, president and chief executive officer, and Mark Lincoln, vice president of Quality Assurance and Operations, have signed a consent decree of permanent injunction.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The consent decree, to be filed in the U.S. District Court for the Eastern District of Michigan by the Department of Justice, Office of Consumer Litigation, and the United States Attorney's Office, prohibits the company from manufacturing and distributing two heart-lung bypass systems and other cardiovascular devices to new customers.

The consent decree also restricts sale of these systems to existing customers until TCVS complies with the FDA's current Good Manufacturing Practice (cGMP) and Medical Device Reporting (MDR) requirements.

TCVS also agreed to pay the federal government $35 million in disgorgement of profits derived from past sales and additional disgorgement amounts should it fail to comply with the provisions of the consent decree in an effective and timely manner.

"Medical device manufacturers must comply with the FDA's current Good Manufacturing Practice and Medical Device Reporting requirements, as this action demonstrates," said Steven Silverman, director of the Office of Compliance in the FDA's Center for Devices and Radiological Health. "These requirements protect patients by assuring that medical devices are safe, effective, and high quality."

During an inspection from January through March 2010, FDA investigators observed numerous cGMP and MDR violations at the company's Ann Arbor manufacturing facility. The violations included deficiencies in processes for corrective and preventive action, nonconforming product, complaints, purchasing, process validation, design controls, and adverse event reporting.

The FDA has twice warned TCVS about its cGMP problems, issuing warning letters to the company in 2004 and in 2006.

Heart-lung bypass systems, also called perfusion systems, keep blood circulating and oxygenated by temporarily taking over the function of the heart and lungs during cardiac or thoracic surgery.

The consent decree restricts the company from distributing and manufacturing the following products:

  • Terumo Advanced Perfusion System 1
  • Sarns Modular Perfusion System 8000
  • Sarns Centrifugal System
  • HX2 Temperature Management System
  • Sarns TCMII Cooling and Heating System
  • CDI 500 Blood Parameter Monitoring System
  • Sarns Sternal Saw II System and Replacement Blades
  • T-Link Data Management Systems (Software Upgrades)
  • Cannulae for cardiopulmonary bypass
  • Cannulae for cardioplegia delivery
  • Vents, suckers, dilators, connectors, and reducers.

The company must also stop distributing the CDI 101 Hematocrit/Oxygen Saturation Monitoring System, which has yet to be reviewed by the FDA.

Because of concerns about possible shortages, the consent decree does not require TCVS to remove the listed products from the market. The company will be allowed to continue to provide service, replacement parts, and loaner devices to existing customers that submit documentation of medical need.

TCVS will be sending its customers a notification guide, which will include instructions for completing and returning a certificate of medical necessity. Its customers can contact the company by phone at 1-800-521-2818 or by email at cardiovascular@terumomedical.com.  TCVS plans to establish a customer website: www.terumo-cvs.com/consentdecree.

The decree becomes effective when it has been filed with and entered by the court.

For more information

Aug. 31, 2004 FDA Warning Letter to Terumo Cardiovascular Systems

Aug. 31, 2006 FDA Warning Letter to Terumo Cardiovascular Systems

Media Inquiries: Karen Riley, 301-796-4674; karen.riley@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zell Lurie Institute Awards $106,300 to University of Michigan Students Through the Michigan Business Challenge and Dare to Dream Startup Grant Program
2. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
3. SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System
4. Exciting Healthcare News for Women of Mid Michigan
5. Southeastern Michigan Gets First Ever FDA Approved Device That Destroys Fat Cells ... Without Surgery
6. Business Accelerator Network for Southeast Michigan Announces Accelerate Michigan Innovation Competition
7. Michigan Home Medical Providers Call on Congress to Preserve Homecare as an Option for Seniors and People With Disabilities Under Medicare
8. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
9. Karmanos Cancer Center Surgeon is Michigans First to Perform Transoral Robotic Surgery on Patients
10. Diabetics Twice as Likely to Have Hearing Loss; Michigan HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
11. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Michigan Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016  Avista ... appointed Eric Setzer as Chief Financial Officer (CFO). ... over twenty years of experience in various roles within ... Avista Pharma, he served as the Executive Director of ... organization in Raleigh, NC . Previously, ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... 2016 Palatin Technologies, Inc. (NYSE MKT: ... therapeutics for the treatment of diseases with significant ... that the United States Patent and Trademark Office ... U.S. Patent Application Serial Number 14/313,258 (the ,258 ... treating female sexual dysfunction using the formulation and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
Breaking Medicine News(10 mins):